18 October 2022 - Version 3 notes 9 amendments, including the withdrawal of a resubmission for a new medicine.
Amgen has withdrawn its submission for sotorasib (Lumakras) for certain patients with non-small-cell lung cancer. Could we see a resubmission at a later date that includes the results from the CodeBreak 200 clinical trial? We shall have to wait and see.